Skip to main content
SpringerLink
Log in

R-DHAP is effective in fludarabine-refractory chronic lymphocytic leukemia

  • Letter to the Editor
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1

References

  1. Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99: 3554–3561.

    Article  CAS  Google Scholar 

  2. Tam CS, Wierda WG, O’Brien S, Lerner S, Khouri IF, Kantarjian HM et al. Life after fludarabine, cyclophosphamide, & rituximab (FCR)—the clinical outcome of patients with chronic lymphocytic leukemia who receive salvage treatment after frontline FCR. Blood 2008; 112: 727.

    Google Scholar 

  3. Vellenga E, van Putten WL, van ‘t Veer MB, Zijlstra JM, Fibbe WE, van Oers MH et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood 2008; 111: 537–543.

    Article  CAS  Google Scholar 

  4. Moufarij MA, Sampath D, Keating MJ, Plunkett W . Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal. Blood 2006; 108: 4187–4193.

    Article  CAS  Google Scholar 

  5. Majolino I, Ladetto M, Locasciulli A, Drandi D, Benedetti F, Gallamini A et al. High-risk fludarabine-pretreated B-cell chronic lymphocytic Leukemia's high response rate following sequential DHAP and alemtuzumab administration though in absence of molecular remission. Med Oncol 2006; 23: 359–368.

    Article  CAS  Google Scholar 

  6. Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O’Brien S, Wen S et al. Phase I–II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2008; 26: 196–203.

    Article  CAS  Google Scholar 

  7. Tsimberidou AM, Keating MJ . Treatment of fludarabine-refractory chronic lymphocytic leukemia. Cancer 2009; 115: 2824–2836.

    Article  CAS  Google Scholar 

  8. Kaspers GJ, Veerman AJ, Pieters R, Van Zantwijk I, Hahlen K, van Wering ER . Drug combination testing in acute lymphoblastic leukemia using the MTT assay. Leuk Res 1995; 19: 175–181.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank GA Huls, MD PhD (University Medical Center, Groningen), S Hovenga, MD PhD (Nij Smellinghe Hospital, Drachten) and SH Wittebol, MD (Meander Medical Center, Amersfoort) for providing patient data. APK is personally supported by a ‘Veni’-grant from the Netherlands Organization for Health Research and Development.

Author information

Authors and Affiliations

  1. Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands

    S H Tonino, M H van Oers & A P Kater

  2. Department of Experimental Immunology, Academic Medical Center, Amsterdam, The Netherlands

    S H Tonino & E Eldering

  3. Department of Hematology, Maastricht University Medical Center, Maastricht, The Netherlands

    M van Gelder

Authors
  1. S H Tonino
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M van Gelder
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E Eldering
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M H van Oers
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A P Kater
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A P Kater.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tonino, S., van Gelder, M., Eldering, E. et al. R-DHAP is effective in fludarabine-refractory chronic lymphocytic leukemia. Leukemia 24, 652–654 (2010). https://doi.org/10.1038/leu.2009.240

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2009.240

  • Springer Nature Limited

This article is cited by

Search

Navigation